Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals In Focus
Zacks Investment Research | Dec 13, 2018 08:19PM ET
While AstraZeneca’s (NYSE:AZN) Imfinzi failed in a late-stage head & neck cancer study this week, Roche (OTC:RHHBY) gained FDA approval for a combination of its cancer drugs Tecentriq+Avastin for the first-line treatment of certain lung cancer patients. Eli Lilly (NYSE:LLY) & Bristol Myers (NYSE:BMY) signed new collaboration deals.
Recap of the Week’s Most Important Stories
Lilly’s New Alzheimer’s Collaboration: Eli Lilly announced a collaboration agreement with Swiss biotech head-to-head study comparing the efficacy of its plaque psoriasis drug, Tremfya to market leader Novartis’ Cosentyx. The data showed that after 48 weeks of treatment, 84.5% of the patients treated with Tremfya achieved 90% improvement in disease symptoms, as measured by the Psoriasis Area Severity Index, compared with 70% on Novartis's Cosentyx.
Novartis’ Xolair Gets EU Nod for Self-Injection Option: The European Commission gave approval to Novartis’ (NYSE:NVS) Xolair prefilled syringe (PFS) for self administration in severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU). The Xolair PFS gives patients the option to self-inject or be injected by a trained caregiver, thereby decreasing the number of regular clinic visits and reduce the burden of such diseases.
The NYSE ARCA Pharmaceutical Index rose 1% in the last five trading sessions.
Here is how the seven major stocks performed in the last five trading sessions:
While J&J and Glaxo recorded the highest gain (1.3%), Pfizer (NYSE:PFE) declined the most (1%) in the last five trading sessions.
In the past six months, Lilly remains the biggest gainer (32.2%) while Glaxo declined the most (8.5%).
(See the last pharma stock roundup here: Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.